MORPHOSYS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67 EUR | 0.00% |
|
+0.53% | +97.06% |
| May. 06 | MORPHOSYS : UBS reiterates its Neutral rating | ZD |
| Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 123M 132M | Sales 2025 * | 325M 350M | Capitalization | 2.52B 2.72B |
|---|---|---|---|---|---|
| Net income 2024 * | -430M -463M | Net income 2025 * | -116M -125M | EV / Sales 2024 * | 21.3 x |
| Net Debt 2024 * | 89.28M 96.15M | Net cash position 2025 * | 94.69M 102M | EV / Sales 2025 * | 7.47 x |
| P/E ratio 2024 * |
-5.93
x | P/E ratio 2025 * |
-32.2
x | Employees | 464 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on MorphoSys AG
More press releases
More news
| 1 week | +0.53% | ||
| Current month | +1.21% | ||
| 1 month | -0.22% | ||
| 3 months | +3.88% | ||
| 6 months | +131.03% | ||
| Current year | +97.06% |
1 week
66.40
67.25
1 month
65.2068.00
Current year
29.7368.00
1 year
14.5268.00
3 years
11.8172.84
5 years
11.81146.30
10 years
11.81146.30
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 19-08-31 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 23-08-06 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 18-05-16 |
| Director/Board Member | 67 | 18-05-16 | |
Marc Cluzel
CHM | Chairman | 69 | 12-05-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.44% | 125 M€ | -.--% | ||
| 0.80% | 17 M€ | -.--% | - | |
| 0.11% | 2 M€ | -.--% | ||
| 0.02% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 67 | 0.00% | 81,536 |
| 24-05-09 | 67 | +0.37% | 77,473 |
| 24-05-08 | 66.75 | -0.07% | 106,985 |
| 24-05-07 | 66.8 | -0.15% | 56,424 |
| 24-05-06 | 66.9 | +0.38% | 46,604 |
Delayed Quote Xetra, May 10, 2024 at 11:35 am EDT
More quotes
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67
EUR
Average target price
58.71
EUR
Spread / Average Target
-12.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +97.06% | 2.72B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- MOR Stock